We are committed to build a world-leading Inhalation medicines company
Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a definitive agreement with INTO (Inhalation Together) to develop TRB-5, TRB-6 and TRB-7, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). INTO is an alliance in the field of inhalation product development to provide formulation services for respiratory products.
TRB-5, TRB-6 and TRB-7, marking the expansion of Transpire Bio into different device and formulation technologies, are inhaled products being developed for the US and European markets. With a focus on complex device, formulation and manufacturing process, these three new products will establish Transpire Bio as a capable drug developer in the inhalation space, bringing new, complex inhaled medicines to market.
“We have been carefully planning to expand our technical capabilities in order to improve access to a broader portfolio of life-saving inhaled therapies, which will also help us better address areas of significant unmet medical needs,” said Dr. Xian-Ming Zeng, CEO of Transpire Bio. “With TRB-5, TRB-6, and TRB-7 we are tackling the complexities of inhaled drug development by harnessing the capabilities of long-trusted partners. We are very excited to be working with INTO and their associated companies to advance these important medicines.”
Thomas Weller, CEO of Harro Höfliger, representing INTO added: “We are very pleased to be selected as a partner by Transpire Bio and we look forward to leveraging our collective experience and products in support of their broad access to complex medicines and solutions to unmet needs ”
According to statistics from the World Health Organization, asthma affected approximately 262 million people in 2019, and accounted for approximately 455,000 deaths. COPD was the third-leading cause of death in 2019, with approximately 3.2 million lives lost.
Transpire Bio Inc. is a US-based, development-stage biopharmaceutical company headquartered in Miami, Florida. The mission of Transpire Bio is to harness the power of inhaled drug delivery to improve patient access to important therapies and develop treatments for serious diseases where therapeutic options are significantly lacking. Transpire Bio develops multiple inhaled approaches, including metered-dose inhalers, soft-mist inhalers, and dry powder inhalers.
For more information, please visit www.transpirebio.com, info@transpirebio.com +1 954.315.0224
“Into is a unique alliance between DFE Pharma, Harro Höfliger and Sterling SpA, combining to support Respiratory product Development, INTO offers a wealth of experience, services and products as a fully aligned single point of contact, clients leverage our collective accountability to economically and efficiently increase speed to market.” To learn more, please visit www.intoinhalation.com/
Sunny Zhao, Manager at Transpire Bio, Sunny.Zhao@Transpirebio.com